Core Viewpoint - Innovation Medical (002173.SZ) reported its 2025 semi-annual results, indicating a decrease in institutional investor holdings compared to the previous quarter [1] Institutional Holdings - As of August 8, 2025, five institutional investors disclosed holdings in Innovation Medical A-shares, totaling 41.4963 million shares, which represents 9.40% of the total share capital [1] - The institutional investor group includes Shanghai Guanghuan Technology Co., Ltd., Hangzhou Changjian Investment Partnership (Limited Partnership), BARCLAYS BANK PLC, Goldman Sachs International - Proprietary Capital, and BNP Paribas - Proprietary Capital [1] - The total institutional holding percentage decreased by 4.25 percentage points compared to the previous quarter [1] Foreign Investment - One foreign fund, BARCLAYS BANK PLC, increased its holdings in this period, accounting for a 0.19% increase [1] - A new foreign institution disclosed this quarter is Goldman Sachs International - Proprietary Capital [1] - The foreign institution that did not disclose its holdings this quarter is MORGAN STANLEY & CO. INTERNATIONAL PLC [1]

证券代码：002173 证券简称：创新医疗 公告编号：2025-044 创新医疗管理股份有限公司关于持股 5%以上股东、 董事、高管减持计划期间届满暨实施结果的公告 持股5%以上股东上海洸焕科技有限公司、董事阮光寅、总裁代行财务总监 马建建保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 创新医疗管理股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日在巨 潮资讯网（www.cninfo.com.cn）上披露了《关于持股 5%以上股东、董事、高管 减持股份的预披露公告》（公告编号：2025-010）。上海洸焕科技有限公司（以 下简称"上海洸焕"）持有公司股份 33,720,222 股，占公司总股本的 7.6414%， 计划自公告之日起 15 个交易日后的三个月内，以集中竞价交易、大宗交易方式 减持本公司股份，减持数量不超过 13,238,487 股，即不超过公司总股本的 3%。 公司董事阮光寅持有本公司股份 1,921,087 股，占公司总股本的 0.4353%，计划 自公告之日起 15 个交易 ...